Mason, OH (PRWEB) August 18, 2014

Assurex Health, a leading personalized medicine company, announced that 100,000 mental health and chronic pain patients across North America have now been tested with GeneSight products that help clinicians select medications based on patients individual genetic profile.

This means that 100,000 people were helped on the road to mental wellness with GeneSight as an integral part of informing their treatment decisions, said Virginia C. Drosos, CEO of Assurex Health. We hope to bring the value of GeneSight to many more clinicians and patients who are working together to manage their mental health, chronic pain, and ADHD.

GeneSight helps health care providers make mental health and chronic pain treatment decisions based on a patients unique genetic makeup. Administered using a simple cheek swab, GeneSight is becoming a preferred step in helping clinicians treat patients with conditions such as depression, PTSD, bipolar disorder, chronic pain, and ADHD.

Many clinicians are making GeneSight the standard of care in their practices, said Joel Winner, M.D., Medical Director of Assurex Health and a practicing psychiatrist in Colorado. GeneSight is extremely beneficial in helping to identify genetically appropriate medications for patients. It gives us more precise information, so we can more quickly help patients get better.

Rapid Growth Expected to Continue

The number of patients tested using GeneSight has doubled since 2012, and is on pace to double again in 2014. Assurex Health expects up to one million patients could be tested by 2018.

Founded in 2006, Assurex Health has grown rapidly to service clinicians and patients throughout the U.S. and has recently expanded internationally through a partnership with Canadas Centre for Addiction and Mental Health (CAMH). Today, more than 8,500 clinicians in private practice, health systems, long-term care facilities and other care sites are registered to offer GeneSight.

Assurex Health recently secured $32 million in additional financing from GE Capital, Silicon Valley Bank, Sequoia Capital, Claremont Creek Ventures, Mayo Clinic, Cincinnati Childrens Hospital Medical Center, CincyTech and Allos Ventures, allowing it to enhance its focus on leading-edge science and delivering clinically proven results and product enhancements.

Assurex Health also recently introduced significantly enhanced versions of its GeneSight Psychotropic and GeneSight Analgesic products and added new commercial health insurance networks to increase patients coverage. In addition, the U.S. Department of Veterans Affairs in June approved use of GeneSight at VA medical centers, the largest health system in the United States, joining Medicare in reimbursing GeneSight.

See the original post:
Mental Wellness Milestone: 100,000 Patients Tested with GeneSight to Support Medication Selection

Comments are closed.